su2083 one-year response and remission rates in ulcerative colitis patients with week 8 response to...
TRANSCRIPT
![Page 1: Su2083 One-Year Response and Remission Rates in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of Ultra 2](https://reader035.vdocuments.site/reader035/viewer/2022081215/575098321a28abbf6bda0f58/html5/thumbnails/1.jpg)
anti-TNF monotherapy does not impact responses relative to non-immunosuppressed con-trols. Booster vaccination with Tdap should ideally be administered prior to immunomodul-ator therapy.Response Rates to Pertussis and Tetanus Antigens by Group
Su2082
Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Amg 181, aFully Human Anti-α4β7 Antibody for Treating Inflammatory Bowel Diseases(IBD)Wei-Jian Pan, Barbara A. Sullivan, Christine M. Evangelista, David R. Doherty, Chi-Yan J.Tam, Sonal K. Patel, Peter J. Prince, Kai O. Reynhardt, William A. Rees, Hailing Hsu,Kefei Zhou, Wen Gu, Mark Yen, Christine A. Haller, Susanna Dodson, Zhigang Yu, LarryC. Wienkers, Dominique C. Borie
Background: To evaluate safety, PK/PD, and tolerability of single subcutaneous (SC) orintravenous (IV) doses of AMG 181 in healthy or ulcerative colitis (UC) subjects. Registeredat www.clinicaltrials.gov under ID NCT01290042 (on-going study sponsored by AmgenInc.). Methods: In this randomized, double-blinded, placebo-controlled, ascending singledose study, 68 healthy male subjects (18-44 yr, 56-121 kg) were randomized and adminis-tered single doses of AMG 181 or placebo (2:1 or 3:1 ratio) at dose levels of 0.7, 2.1, 7,21, 70 mg SC (or IV), 210 mg SC (or IV), and 420 mg IV. Eight UC subjects were randomizedto receive a single dose of 210 mg AMG 181 or placebo SC (3:1 ratio). Serum was collectedfor evaluation of PK and for the presence of anti-drug antibodies (ADA). Whole blood wascollected to assess α4β7 receptor occupancy (RO) and CD4 memory and naïve T cell countsusing a validated whole blood 6-color flow cytometric assay. PK and ADA samples wereassayed using validated electrochemiluminescent immunoassay (ECL) methods with a lowerlimit of quantification (LLOQ) of 10 ng/mL and a lower limit of reliable detection (LLRD)of 20 ng/mL, respectively. Population PK/PD modeling, with demography as covariates, wasconducted on AMG 181 concentration and RO data. The follow-up period was based onpredicted receptor occupancy, AMG 181 half-life and safety monitoring requirements.Results: The median time to Cmax (tmax) for AMG 181 was 2-10 days after SC dosing,with a mean bioavailability of 83%. While Cmax was dose-proportional at 21-210 mg SC,both Cmax and AUCinf were dose-proportional at 70-420 mg IV. AMG 181 clearance waslow (131 mL/day) and its distribution mostly limited within the central circulation (volumeof distribution: 4760 mL). AMG 181 had a linear elimination range half-life of 36 days,with terminal target-mediated disposition occurring below 1 μg/mL. The extent and durationof α4β7 RO increased with AMG 181 dose. The Emax model estimated E0, Emax, andEC50 values for RO were 0.0824, 0.946, and 1.18 ng/mL, respectively. An increase in CD4T cell counts in peripheral blood was not observed. All subjects tested negative for ADA.Preliminary population analyses revealed no demographic effects on AMG 181 PK/PD.Blinded safety data showed a 44% adverse event rate, with no treatment-related ≥Grade 3events, serious adverse events, deaths, or dose limiting toxicities. There were no abnormalitiesin ECGs or neurological exams. No subject discontinued the study due to an adverse event.Conclusion: AMG 181 has proven to be safe and well tolerated with desirable PK/PDproperties under fixed dose regimens. It is suitable for further testing in patients with IBD.
Su2083
One-Year Response and Remission Rates in Ulcerative Colitis Patients WithWeek 8 Response to Adalimumab: Subanalysis of Ultra 2William J. Sandborn, Geert R. D'Haens, Jean-Frederic Colombel, Gert A. Van Assche,Douglas C. Wolf, Martina Kron, Andreas Lazar, Anne Robinson, Jingdong Chao, RoopalThakkar
<p> Background: Physicians are unlikely to continue anti-TNF therapy for ulcerative colitis(UC) patients (pts) not exhibiting early therapeutic response. We evaluated Week (Wk) 52clinical remission and response rates in moderate to severe UC pts failing conventionaltherapy and achieving Wk 8 clinical response in ULTRA 2. <p> Methods: In the 52-wkULTRA 2 trial, pts were randomized 1:1 to adalimumab (ADA; 160/80 mg at Wk 0/2, 40mg every other wk [eow] thereafter) or placebo (PBO). Pts with inadequate response couldswitch to open-label (OL) ADA (40 mg eow, followed by 40 mg weekly) from Wk 12. Wk52 clinical remission (Mayo score ≤2; no subscore >1) and clinical response (Mayo scoredecrease of ≥3 points and ≥30% from baseline and decrease in rectal bleeding score [RBS]≥1 or absolute RBS of 0 or 1) rates were assessed in all PBO pts, in ADA pts achievingclinical response by full Mayo score, and in ADA pts achieving clinical response by partialMayo score (decrease of ≥2 points and ≥30% from baseline and above RBS criteria) at Wk8. Subgroup analyses by prior anti-TNF use were also performed. Non-responder imputation(NRI) was used for missing data or that collected on/after move to OL for PBO and ADA.ADA subgroups were also analyzed using modified NRI (mNRI); only missing data wereimputed as non-response/remission. Response and remission were compared between ADA(NRI or mNRI) and PBO (NRI only) groups. <p> Results: Significantly more ADA-treatedpts in each response group achieved Wk 52 remission or response as compared with PBOpts (Table; all comparisons P<0.01). A similar pattern of results was seen regardless of prioranti-TNF status (Table). <p> Conclusions: In moderate to severe UC pts in ULTRA 2,clinically meaningful long-term efficacy with ADA was seen at Wk 52 in pts with Wk 8 fullor partial Mayo score response.Wk 52 Results in ADA Week 8 Responders (by Full or Partial Mayo Score) and All PBO Pts
S-565 AGA Abstracts
aWk 8 responder per full Mayo score; bWk 8 responder per partial Mayo score; *P<0.01,ADA vs. PBO (CMH test for all, chi square test for anti-TNF subgroups)
Su2084
Efficacy of Certolizumab Pegol Induction and Maintenance Therapy inPatients With Crohn's Disease Not in Remission Following Active or PlaceboInductionWilliam J. Sandborn, Ziad H. Younes, Bosny Pierre-Louis, Geert R. D'Haens
Purpose To evaluate remission rates in patients with active Crohn's disease (CD) afterplacebo induction therapy or certolizumab pegol (CZP) induction or reinduction therapyfor 6 weeks and open-label CZP maintenance therapy for 20 weeks. Methods Patientscompleting the placebo-controlled CZP induction study (study 085, NCT00552058), andwith active disease (Crohn's Disease Activity Index 220-450), were eligible to enter an open-label study (study 088, NCT00552344) and receive open-label CZP 400 mg at Weeks 0,2, 4, and then every 4 weeks (q4w) thereafter. The Inflammatory Bowel Disease Questionnaire(IBDQ) and the CD Activity Index (CDAI) were used to measure remission rates. Remissionrates were analyzed from the baseline (Week 0) of the open-label study in patients whoreceived 6 weeks of induction therapy with CZP 400 mg or placebo in the CZP inductionstudy. Remission rates were calculated using the intention-to-treat population. Results Of439 patients who participated in the CZP induction study, 398 enrolled in the open-labelCZP study (intention-to-treat population). In the CZP induction study, 195 and 203 patientsreceived 6 weeks of placebo or CZP 400 mg, respectively. At baseline of the open-label CZPstudy (Week 0), 74% (144/195) and 60% (122/203) of patients did not achieve IBDQremission (IBDQ score ≥170 points) following 6 weeks of placebo or CZP 400 mg, respect-ively, in the CZP induction study. The mean IBDQ scores at Week 0 were 147 and 154among patients in the placebo and CZP 400 mg groups, respectively. Among patients notin remission at Week 0, IBDQ remission rates were 35% at Week 6 and 32% at Week 20for patients who received placebo induction, and 27% and 26%, respectively, for patientswho received CZP induction (Table). IBDQ remission rates for the total population in theopen-label CZP study at Weeks 6 and 20 were 45% and 42%, respectively, for patientswho received placebo induction, and 48% and 43%, respectively, for patients who receivedCZP induction (Table). Among patients not in remission at Week 0, the CDAI remissionrates (CD Activity Index score ≤150) at Week 6 were 35% (52/148) for patients receivingplacebo and 35% (48/138) for those receiving CZP 400 mg in the CZP induction study.Conclusions Induction or reinduction with open-label CZP 400 mg q4w captured remissionin a subset of patients with active CD following induction therapy with placebo or CZP 400mg. Remission rates with open-label CZP 400 mg q4w were similar to those reported inprevious clinical trials with CZP 400 mg. These data suggest that it may be useful to continueCZP 400 mg q4w treatment even if a patient has failed 6 weeks of CZP induction therapy.
Su2085
Association of Baseline C-Reactive Protein With Maintenance of Remission inAnti-TNF-Experienced Patients With Moderate to Severe Crohn's DiseaseTreated With AdalimumabWilliam J. Sandborn, Jean-Frederic Colombel, Geert R. D'Haens, Anne Robinson, Paul F.Pollack, Qian Zhou, Roopal Thakkar
Introduction: In the pivotal randomized placebo-controlled adalimumab (ADA) maintenancetrial (CHARM1), patients with elevated baseline C-reactive protein (CRP) who achievedclinical response after induction dosing demonstrated numerically higher rates of clinicalremission during maintenance therapy with weekly vs every other week (eow) ADA dosing.We previously reported that there was no difference in maintenance of remission betweendosing groups in the anti-TNF-naïve subgroup of CHARM patients with elevated baselineCRP.2We examined the effect of baseline CRP concentrations on themaintenance of remission
AG
AA
bst
ract
s